Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160393 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL4386268 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL5301933 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL9165455 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL837479 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL4650965 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL868174 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL3149218 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL1703685 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL5302396 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034184-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | EMORY UNIVERSITY (US) | 2025-01-30 | — | — | US | claimed |
| EP-4387628-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | Emory University (US) | 2024-06-26 | — | — | EP | claimed |
| US-20230172879-A1 | THERAPEUTIC METHODS FOR PREVENTING TUMOR METASTASIS AND TUMOR RECURRENCE | LUNELLA BIOTECH, INC. (CA) | 2023-06-08 | — | — | US | claimed |
| EP-4139484-A1 | THERAPEUTIC METHODS FOR PREVENTING TUMOR METASTASIS AND TUMOR RECURRENCE | Lunella Biotech, Inc. (CA) | 2023-03-01 | — | — | EP | claimed |
| WO-2023023113-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | EMORY UNIVERSITY (US) | 2023-02-23 | — | — | WO | claimed |
| WO-2021214727-A1 | THERAPEUTIC METHODS FOR PREVENTING TUMOR METASTASIS AND TUMOR RECURRENCE | LUNELLA BIOTECH, INC. (CA) | 2021-10-28 | — | — | WO | claimed |
| CN-112079679-A | Asymmetric total synthesis method of sex pheromone (R, Z) -21-methyl-8-thirty-five carbene of longicorn | 塔里木大学 | 2020-12-15 | — | — | CN | claimed |
| CN-110028672-A | A kind of sulfur-bearing, nitrogen, oxygen atom comb shape polysulfide ether compound and its preparation method and use | 烟台大学 | 2019-07-19 | — | — | CN | claimed |
| EP-2563375-B1 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS | ALCON RES LTD (US) | 2014-06-25 | — | — | EP | claimed |
| EP-1973974-B1 | A PROCESS FOR PREPARING 'ONIUM SALTS | SUN CHEMICAL CORP (US) | 2014-04-30 | — | — | EP | claimed |
| US-20080287686-A1 | Process for Preparing Onium Salts | SUN CHEMICAL CORP (US) | 2008-11-20 | — | — | US | claimed |
| EP-1973974-A2 | A PROCESS FOR PREPARING 'ONIUM SALTS | Sun Chemical Corporation (US) | 2008-10-01 | — | — | EP | claimed |
| WO-2007075498-A2 | A PROCESS FOR PREPARING 'ONIUM SALTS | SUN CHEMICAL CORPORATION (US) | 2007-07-05 | — | — | WO | claimed |
| EP-1263426-B1 | PREPARATIONS FOR THE NON-TRAUMATIC EXCISION OF A NAIL | KRAEMER KARL (DE) | 2006-03-15 | — | — | EP | claimed |
| EP-1216295-B1 | DETERGENT COMPOSITION COMPRISING A SOIL ENTRAINMENT SYSTEM | PROCTER & GAMBLE (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1250374-B1 | MACROCYCLIC POLYESTER OLIGOMERS AND PROCESSES FOR POLYMERIZING THE SAME | CYCLICS CORP (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040035791-A1 | Formation of hydrophilic sites in partially silylated micelle templated silica | UNIVERSITE LAVAL (CA) | 2004-02-26 | — | — | US | claimed |
| WO-2002016267-A1 | FORMATION OF HYDROPHILIC SITES IN PARTIALLY SILYLATED MICELLE TEMPLATED SILICA | UNIVERSITE LAVAL (CA) | 2002-02-28 | — | — | WO | claimed |
| EP-0877298-B1 | Coated xerographic photographic paper | XEROX CORP (US) | 2001-08-29 | — | — | EP | claimed |
| EP-0346655-B1 | AN IMPROVED METHOD FOR PREPARING POLYMER SURFACES FOR SUBSEQUENT PLATING THEREON, AND IMPROVED METAL-PLATED PLASTIC ARTICLES MADE THEREFROM | GENERAL ELECTRIC COMPANY (US) | 1993-08-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172879-A1 | THERAPEUTIC METHODS FOR PREVENTING TUMOR METASTASIS AND TUMOR RECURRENCE | ACLY, SLC25A6, SLC25A5 | MEN1 4453/4885KMT2A 1940/4885DNM1 1068/4885 |
| US-20080287686-A1 | Process for Preparing Onium Salts | IK, NOTUM, NOS2 | MEN1 3526/4885KMT2A 2078/4885DNM1 1560/4885 |
| US-20250034184-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | CD47, BTK, PHOSPHO1 | MEN1 809/4885KMT2A 711/4885DNM1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.